



PRESS RELEASE

Cenetron Diagnostics Announces Large-Scale Expansion

Addition to facility increases capacities in all operational phases of central lab and CRO

Austin, Texas USA – March 5, 2013 -Cenetron Diagnostics, Ltd today announced today a 42,000 square foot (4500 square meter) expansion of their laboratory, specimen storage, kit manufacturing, and clinical trials management facilities.

Cenetron Diagnostics completed construction and occupied its new, state-of-the art facility, located in Austin, Texas, USA.

Cenetron's expanded facility includes a new clinical trials laboratory for molecular testing, a technology translation laboratory to validate new tests and services prior on-line use, and a 7,000 square foot research and development laboratory.

Within the expanded space, Cenetron has built a large capacity biostorage facility for storage of samples in minus 80 degree freezers, and for long-term storage in liquid nitrogen.

Additionally, Cenetron has tripled the size of its clinical trials kit manufacturing department, to accommodate its rapid growth of its custom kit business.

"We are very excited about this facility expansion," said Dwight DuBois, M.D., President of Cenetron. "The new space will provide our company ample room, in a state-of-the-art environment, for the foreseeable future. Growth of our kit manufacturing and biostorage operations are particularly robust. We are now shipping over 30,000 kits per month, and expect further growth."

Vice-President of Operations, Brandon Harper commented, "Our expanded facility has been purposefully built to optimize our processes, from kit manufacturing through sample storage. The newly designed and expanded space enhances our ability to quickly address the needs of our clients in the ever-changing pharma landscape."

About Cenetron Diagnostics

Cenetron Diagnostics is a premier provider of molecular laboratory services, providing support for anti-viral and oncology drug development programs, and pharmacogenomics. Founded in 1995, Cenetron has supported pivotal global trials in North and South America, Europe, Africa and the Pacific Rim.